prikaz prve stranice dokumenta The Impact of Nonalcoholic Fatty Liver Disease on Severe Community-Acquired Pneumonia Outcomes
  Preuzmi
PDF 1013.93 KB
Znanstveni rad - Izvorni znanstveni rad
The Impact of Nonalcoholic Fatty Liver Disease on Severe Community-Acquired Pneumonia Outcomes
Life, 13 (2022), 1; 36. https://doi.org/10.3390/life13010036
Gjurašin, Branimir; Jeličić, Mia; Kutleša, Marko; Papić, Neven

Citirajte ovaj rad

Gjurašin, B., Jeličić, M., Kutleša, M. i Papić, N. (2022). The Impact of Nonalcoholic Fatty Liver Disease on Severe Community-Acquired Pneumonia Outcomes. Life, 13. (1). doi: 10.3390/life13010036

Gjurašin, Branimir, et al. "The Impact of Nonalcoholic Fatty Liver Disease on Severe Community-Acquired Pneumonia Outcomes." Life, vol. 13, br. 1, 2022. https://doi.org/10.3390/life13010036

Gjurašin, Branimir, Mia Jeličić, Marko Kutleša i Neven Papić. "The Impact of Nonalcoholic Fatty Liver Disease on Severe Community-Acquired Pneumonia Outcomes." Life 13, br. 1 (2022). https://doi.org/10.3390/life13010036

Gjurašin, B., et al. (2022) 'The Impact of Nonalcoholic Fatty Liver Disease on Severe Community-Acquired Pneumonia Outcomes', Life, 13(1). doi: 10.3390/life13010036

Gjurašin B, Jeličić M, Kutleša M, Papić N. The Impact of Nonalcoholic Fatty Liver Disease on Severe Community-Acquired Pneumonia Outcomes. Life [Internet]. 23.12.2022. [pristupljeno 03.12.2024.];13(1). doi: 10.3390/life13010036

B. Gjurašin, M. Jeličić, M. Kutleša i N. Papić, "The Impact of Nonalcoholic Fatty Liver Disease on Severe Community-Acquired Pneumonia Outcomes", Life, vol. 13, br. 1, Prosinac 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:827622. [Citirano: 03.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:827622
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)The Impact of Nonalcoholic Fatty Liver Disease on Severe Community-Acquired Pneumonia Outcomes
AutorBranimir Gjurašin
AutorMia Jeličić
AutorMarko Kutleša
AutorNeven Papić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INFEKTOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Infektologija
Sažetak (engleski)
Community-acquired pneumonia (CAP) is one of the leading causes of morbidity and mortality, while nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. NAFLD is associated with systemic changes in immune response, possibly linked to CAP severity. However, the impact of NAFLD on CAP outcomes has not been determined. The aim of this study was to evaluate clinical course, complications and outcomes of severe CAP requiring ICU treatment in patients with NAFLD in the pre-COVID-19 era. A retrospective cohort study included 138 consecutively hospitalized adult patients with severe CAP admitted to the ICU during a 4-year period: 80 patients with NAFLD and 58 controls. Patients with NAFLD more frequently presented with ARDS (68.7% vs. 43.1%), and required invasive mechanical ventilation (86.2% vs. 63.8%), respiratory ECMO (50% vs. 24.1%), and continuous renal replacement therapy (62.5% vs. 29.3%). Mortality was significantly higher in the NAFLD group (50% vs. 20.7%), and the time from hospital admission to death was significantly shorter. In survival analysis, NAFLD (HR 2.21, 95%CI 1.03–5.06) was associated with mortality independently of other components of metabolic syndrome. In conclusion, our study identified NAFLD as an independent predictor of mortality in patients with severe CAP.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaLife
Brojčani podacivol. 13, br. 1, 36
e-ISSN2075-1729
DOIhttps://doi.org/10.3390/life13010036
URN:NBNurn:nbn:hr:105:827622
Datum objave publikacije2022-12-23
ProjektŠifra: UIP-2019-04-7194
Naziv (hrvatski): Uloga imunih semaforina u nealkoholnoj masnoj bolesti jetre i sepsi
Naziv (engleski): The role of immune semaphorins in NAFLD and sepsis
Kratica: SepsisFAT
Voditelj: Neven Papić
Pravna nadležnost: Hrvatska
Financijer: HRZZ
Linija financiranja: UIP
URL dokumentahttps://www.mdpi.com/2075-1729/13/1/36
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-01-23 09:40:38